Axel S Merseburger: Mitomycin pyelocalyceal: non-surgical treatment for patients with low-grade UTUC

We are joined by our Editor-in-Chief for European Oncology & Haematology, Axel S Merseburger, to discuss the recent FDA approval of mitomycin pyelocalyceal for low-grade upper tract urothelial cancer. This is based on results from the OLYMPUS (NCT02793128) trial, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naïve or recurrent low-grade non-invasive UTUC with at least one measurable papillary tumor located above the ureteropelvic junction.

Questions
1. Before the approval of mitomycin pyelocalyceal, how was low-grade upper tract urothelial cancer treated, and what are the treatment challenges associated with the upper urinary tract? (0:06)
2. How is the gel administered and what is the treatment regimen? (0:52)
3. Could you tell us about the aims, design and inclusion criteria of the OLYMPUS trial? (1:56)
4. What were the major efficacy and safety findings of this trial? (3:16)
5. What patients are most likely to benefit from this therapy and how might it impact the future of urothelial cancer? (4:10)

Axel S Merseburger has no conflicts of interest to declare in relation to this video.

Commissioned, edited and funded by Touch Medical Media

Published: 14 May 2020